Uniseed is Australia’s longest running venture fund, operating at the Universities of Melbourne, Queensland, Sydney & New South Wales, and the CSIRO, with investment capital provided by these research organisations and a leading Australian Superannuation Fund, UniSuper. These research organisations collectively spend $4 billion on research annually, making up over 40% of the total research spend in all research organisations in Australia.
In November 2015, Uniseed started its third and largest fund (Fund-3), with the five partners each committing $10 million over 10 years (total fund $50 million). This followed three high profile exits in the preceding 14 months (Fibrotech sale to Shire; Spinifex sale to Novartis & Hatchtech sale to Dr Reddys Laboratories).
In March 2017, Uniseed announced the further commitment to a $20 million Follow-on Fund.
In January 2018, a Co-Investment Fund was established with private capital providers through a relationship with Stoic Venture Capital.
In March 2022, Uniseed announced strategic partnership and a further commitment of $75 million from leading Australian superannuation fund UniSuper.
Hear what Researchers and CEO’s of Uniseed startups say about working with Uniseed.